Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV

A prospective, randomized, multicenter noninferiority study comparing the regiments of tenofovir DF, emtricitabine and efavirenz and a fixed dose of zidovudine and lamivudine plus efavirenz were conducted. Results revealed that the combination of tenofovir DF and emtricitabine plus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs.